STAT3/STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma

Area of Science:

• Hematologic Malignancies
• Cancer Genomics
• Molecular Pathology

Background:

• Plasma cell myeloma is a heterogeneous hematologic malignancy.
• RAS-MAPK pathway mutations are known high-risk features in myeloma.
• The clinical significance of STAT3/STAT5 mutations in myeloma is not well understood.

Purpose of the Study:

• To investigate the clinical relevance and prognostic impact of STAT3/STAT5 mutations in plasma cell myeloma.
• To determine if STAT3/STAT5 mutations are early or late events in myeloma pathogenesis.
• To explore the association of STAT3/STAT5 mutations with other genetic alterations and clinical features.

Main Methods:

• Next-generation sequencing was used to identify STAT3/STAT5 mutations in 16 myeloma patients.
• Mutation-negative patients served as controls (n=32).
• Clinical data, including survival, cytogenetics, and serum markers, were analyzed and compared between mutated and control groups.

Main Results:

• STAT3/STAT5 mutations were identified as early and often dominant events in myeloma pathogenesis.
• These mutations were frequently co-occurring with other mutations, notably in KRAS/NRAS and TP53.
• Patients with STAT3/STAT5 mutations exhibited adverse clinical features, including higher R-ISS stage and complex karyotype, and significantly shorter overall survival (42 vs. 72 months).

Conclusions:

• STAT3/STAT5 mutations are early, dominant, and potentially pathogenic drivers in plasma cell myeloma.
• The presence of these mutations is associated with unfavorable clinical characteristics and inferior patient survival.
• Routine assessment of STAT3/STAT5 mutations is warranted for risk stratification and may inform therapeutic strategies in myeloma.